Takeda seeks dengue vaccine inclusion in India's immunization program

Takeda Pharmaceutical is seeking to have its dengue vaccine included in India's national immunization program. The company is in discussions with Indian health authorities to add the vaccine to the country's routine vaccination schedule, which would significantly expand access to the vaccine in a country with a high burden of dengue cases. Dengue is a mosquito-borne viral infection that causes severe flu-like symptoms and can be fatal, particularly in children. India reports hundreds of thousands of cases annually, making it a key market for dengue vaccines. Takeda's vaccine, Qdenga, has been approved in several countries and is being rolled out globally. Inclusion in India's program would mark a major public health milestone and a commercial win for Takeda, potentially reaching millions of people. The timeline for a decision is unclear, but the company is actively engaging with regulators and policymakers.

Global Impact

Inclusion in India's immunization program would be a significant public health achievement, potentially reducing dengue morbidity and mortality in one of the world's most affected countries. Economically, it would create a large vaccine market, benefiting Takeda and potentially spurring competition from other manufacturers.